Eiko Lifesciences (BOM:540204) ROCE %: 11.54% (As of Mar. 2026)


BOM:540204 Eiko Lifesciences Ltd BOM:540204
78 GF Score
Price ₹49.72
GF Value ₹78.58
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Eiko Lifesciences ROCE %?

Eiko Lifesciences BOM:540204 -1.43% 78 ROCE % is 11.54% as of Mar. 2026. GuruFocus rates BOM:540204 with a GF Score™ of 78/100 and a GF Value™ of ₹78.58 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Eiko Lifesciences's annualized ROCE % for the quarter that ended in Mar. 2026 was 11.54%.

Eiko Lifesciences  (BOM:540204) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Eiko Lifesciences ROCE % Related Terms

Eiko Lifesciences ROCE % Historical Data

* Premium members only.

The historical data trend for Eiko Lifesciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiko Lifesciences ROCE % Chart

Eiko Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.31 4.01 2.78 5.80 11.13

Eiko Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.39 10.25 11.80 12.83 11.54
BOM:540204
78GF Score
Eiko Lifesciences Ltd BOM:540204
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eiko Lifesciences ROCE % Calculation

Eiko Lifesciences's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=74.474/( ( (661.013 - 62.654) + (893.697 - 153.793) )/ 2 )
=74.474/( (598.359+739.904)/ 2 )
=74.474/669.1315
=11.13 %

Eiko Lifesciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=85.352/( ( (0 - 0) + (893.697 - 153.793) )/ 1 )
=85.352/( ( 0 + 739.904 )/ 1 )
=85.352/739.904
=11.54 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 11.54% mean?
Eiko Lifesciences (BOM:540204) has a ROCE % of 11.54% as of Mar. 2026.
Is Eiko Lifesciences' ROCE % too high?
Eiko Lifesciences' current ROCE % is 11.54%. The Chemicals industry median ROCE % is 6.42. Eiko Lifesciences' value of 11.54% is 79.8% above this industry median. Overall, Eiko Lifesciences has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eiko Lifesciences' ROCE % compare to LIN and SHW?
Eiko Lifesciences' ROCE % of 11.54% can be compared against companies in the Chemicals industry. The industry median ROCE % is 6.42. Eiko Lifesciences' value of 11.54% is 79.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Chemicals company?
The median ROCE % among Chemicals companies is 6.42, based on 1,589 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eiko Lifesciences's current ROCE % of 11.54% is 79.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Chemicals industry, the median ROCE % is 6.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eiko Lifesciences's current ROCE % is 11.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiko Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eiko Lifesciences (BOM:540204) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹78.58, compared to a current price of ₹49.72 — trading 36.7% below its estimated fair value. The current ROCE % is 11.54% and 79.8% above the Chemicals industry median of 6.42. Eiko Lifesciences' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Eiko Lifesciences (BOM:540204), the current ROCE % is 11.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eiko Lifesciences (BOM:540204) Overvalued in 2026?

Based on GuruFocus' analysis, Eiko Lifesciences stock appears to be undervalued. The current stock price of ₹49.72 is trading 36.7% below its estimated GF Value™ of ₹78.58. GuruFocus considers Eiko Lifesciences to be Significantly Undervalued.

Key valuation signals for BOM:540204:

  • ROCE %: 11.54%
  • GF Value™: ₹78.58 vs. price of ₹49.72 (36.7% below fair value)
  • GF Score™: 78/100 with 1 warning sign
  • Industry Position: 79.8% above the Chemicals median

No single metric tells the full story. See the BOM:540204 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eiko Lifesciences Business Description

Address 604, Centrum, Wagle Estate, Opposite TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane, MH, IND, 400604
Eiko Lifesciences Ltd is a manufacturer, supplier, and exporter of specialty chemicals, fine chemicals, and pharma intermediates.. The company's segment includes Agrochemicals, Oleo Chemicals, Pharmaceuticals, Food Additives, clinical research, development, and Logistics. Geographically, the company generates the majority of its revenue from the Domestic market.
78GF Score

Get the complete analysis for BOM:540204

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹49.72
Price
₹78.58
GF Value